Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that topical finasteride significantly increased hair count in men with androgenetic alopecia compared to placebo while maintaining similar efficacy to oral finasteride but with lower systemic exposure and a reduced impact on serum DHT levels, potentially minimizing sexual side effects.

This article reviews 27 small-molecule drugs approved by the FDA in 2024, noting that among them, eight "first-in-class" drugs with breakthrough therapy status show distinct mechanisms and substantial efficacy improvements in various conditions like cancer and chronic diseases.

This study reported that ZSYY001, a nanoparticle formulation of polymeric micellar paclitaxel, showed promising antitumor activity and was safe and well-tolerated in preclinical models and a phase I trial, without acute hypersensitivity reactions at doses up to 390 mg/m².

In this study, an ultra-low dose combination of estradiol and dydrogesterone significantly reduced hot flushes and improved health-related quality of life among a multi-ethnic population of postmenopausal women, with no notable difference in serious adverse events compared to placebo.

In this study, ritlecitinib was generally well tolerated in pediatric alopecia areata patients aged 6 to <12 years, with no severe or serious adverse events reported, and the drug's pharmacokinetic parameters were successfully characterized.

This study found that oral setipiprant was safe but did not improve scalp hair growth compared to placebo in men with androgenetic alopecia.

Early diagnosis, innovative treatments, and considering systemic conditions are crucial in dermatological care.

This article provides industry updates on stem cell research and regenerative medicine from December 2019 and reports no new research findings.

This study evaluated two bimatoprost 1% formulations for androgenetic alopecia in men, finding both formulations achieved effective drug concentrations in the scalp with no significant differences between them, and were well tolerated over the 14-day application period.

This research describes CG2001's promising safety profile and reduced systemic exposure as an alternative to finasteride, supporting its further development for androgenic alopecia treatment in future trials.

This study is investigating the efficacy and safety of proxalutamide, an androgen receptor antagonist, in treating severe or critically ill patients with COVID-19, aiming to provide new insights into potential therapeutic options. Results are not reported yet.

This study highlights IGF-1's role in promoting hair follicle proliferation, vascularization, and growth, suggesting its potential as a treatment target for hair loss disorders like androgenetic alopecia, though more research on delivery methods and long-term effects is needed.

This randomized, double-blind, placebo-controlled phase III trial found that a 24-week treatment with topical finasteride significantly increased hair growth and was well-tolerated in Chinese men with androgenetic alopecia compared to placebo.

In this study, 0.2 mg dutasteride significantly improved hair growth in men with androgenetic alopecia compared to placebo over 24 weeks, showing similar efficacy to the higher 0.5 mg dose with a favorable safety profile.

In this analysis, JAK inhibitors were found to provide clinically meaningful and durable hair regrowth in pediatric alopecia areata, outperforming traditional therapies with a manageable safety profile.

This study found that eribulin-based chemotherapy resulted in longer median progression-free and overall survival, with fewer side effects, for advanced triple-negative breast cancer patients compared to other chemotherapy options.

Temporal triangular alopecia is a non-scarring hair loss seen in some Asian children.

In this study, researchers developed a novel TA-encapsulated microneedle applicator that successfully promoted hair growth and reduced inflammation in a C3H/HeJ mouse model of alopecia areata, potentially offering an improved alternative to existing treatments.

This case series reported that telogen effluvium may reveal underlying traction alopecia, emphasizing the importance of recognizing this to ensure accurate diagnosis and treatment.

This study found that tenuazonic acid from Alternaria alternata can cause significant damage to vital organs in mice at low doses and highlights the need for regulatory measures to manage its risk in agricultural products.

This study found that the tetracycline-regulated transcription system effectively controls conditional gene expression in the mouse epidermis, allowing suppression and activation of specific genes with doxycycline.

5α-reductase inhibitors may cause persistent sexual dysfunction and depression, needing more research on long-term effects.

This case report details a 57-year-old woman with frontal fibrosing alopecia who developed hyperpigmentation after treatment with dutasteride and pimecrolimus, highlighting no previously reported hyperpigmentation association with this combination.

Among a Han Chinese cohort, this study found that a higher genetic risk score was linked to increased susceptibility to BPH, larger prostate size, reduced effectiveness of 5ARI treatment, and a higher risk of undergoing TURP.

This review reported that while finasteride is effective for treating androgenetic alopecia and benign prostatic hyperplasia, it may cause adverse effects such as sexual dysfunction and psychological symptoms, which require careful patient education and management to ensure treatment adherence and satisfaction.

In this study of BPH patients with testosterone deficiency, the combination of TU and dutasteride reduced prostate volume and improved testosterone-related symptoms but was less effective for sexual function compared to TU alone, indicating caution in using dutasteride for those with sexual dysfunction concerns.

This study found that global online interest in finasteride and its sexual side effects significantly increased after the FDA issued safety warnings in 2011.

This study observed that multiple familial trichoepitheliomas commonly presented with a cribriform histopathological tumor pattern, differentiating them from solitary trichoepitheliomas.

In this study, researchers identified a cluster of hair-specific keratin-associated protein genes within the 21q22.3 region, revealing a novel transcription mechanism involving TSPEAR/C21orf29 that may bypass typical transcriptional termination sites.